Abstract | BACKGROUND:
Paclitaxel has been described to induce interleukin-8 (IL-8) transcription and secretion in human ovarian carcinoma cells. The objective of this study was to investigate possible clinical implications of the effect of paclitaxel on IL-8 serum levels in patients suffering from ovarian carcinoma. METHODS: RESULTS: Seventy-eight percent of patients responded to chemotherapy, with 61% achieving a complete response and 16% achieving a partial response. The median IL-8 serum level before chemotherapy was 75 pg/mL (range, 2.7-903.3 pg/mL), the level during chemotherapy was 23.75 pg/mL (range, 0.5-248.2 pg/mL), and the level after chemotherapy was 17.65 pg/mL (range, 0.6-377.0 pg/mL). The median IL-8 serum level in controls was 15.6 pg/mL (range, 1.4-106.3 pg/mL). The authors found a statistically significant decrease in both IL-8 serum levels (P < 0.05 and P < 0.05) and CA 125 serum levels (P < 0.05 and P < 0.05) from the first to the second measurement and from the first to the third measurement, respectively. They found no correlation between the shifts of IL-8 serum levels and CA 125 serum levels during chemotherapy. CONCLUSIONS: The authors found a significant decrease in IL-8 serum levels in patients undergoing a paclitaxel-containing chemotherapy regimen, indicating that IL-8 possibly acts as a useful monitoring marker in patients with ovarian carcinoma.
|
Authors | K Mayerhofer, K Bodner, B Bodner-Adler, M Schindl, A Kaider, L Hefler, R Zeillinger, S Leodolter, E A Joura, C Kainz |
Journal | Cancer
(Cancer)
Vol. 91
Issue 2
Pg. 388-93
(Jan 15 2001)
ISSN: 0008-543X [Print] United States |
PMID | 11180086
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- CA-125 Antigen
- Interleukin-8
- Neoplasm Proteins
- Carboplatin
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- CA-125 Antigen
(blood)
- Carboplatin
(administration & dosage)
- Case-Control Studies
- Female
- Follow-Up Studies
- Humans
- Interleukin-8
(blood)
- Middle Aged
- Neoplasm Proteins
(blood)
- Ovarian Neoplasms
(blood, drug therapy)
- Paclitaxel
(administration & dosage)
|